(Q44623798)

English

Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome

scientific article published in December 2011

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

4 December 2017

Impact of the conversion of the immunosuppressive regimen from prograf to advagraf or to sirolimus in long-term stable liver transplant recipients: indications, safety, and outcome (English)

1 reference

Europe PubMed Central

4 December 2017

1 reference

based on heuristic

inferred from title

author name string

A Perrakis

1

1 reference

Europe PubMed Central

4 December 2017

K Schwarz

2

1 reference

Europe PubMed Central

4 December 2017

S Yedibela

3

1 reference

Europe PubMed Central

4 December 2017

R S Croner

4

1 reference

Europe PubMed Central

4 December 2017

W Hohenberger

5

1 reference

Europe PubMed Central

4 December 2017

V Müller

6

1 reference

Europe PubMed Central

4 December 2017

language of work or name

0 references

publication date

1 December 2011

1 reference

Europe PubMed Central

4 December 2017

Transplantation Proceedings

1 reference

Europe PubMed Central

4 December 2017

43

1 reference

Europe PubMed Central

4 December 2017

3702-3707

1 reference

Europe PubMed Central

4 December 2017

10

1 reference

Europe PubMed Central

4 December 2017

Immunosuppression after liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Early steroid-free immunosuppression with FK506 after liver transplantation: long-term results of a prospectively randomized double-blinded trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Four-year experience with tacrolimus once-daily prolonged release in patients from phase II conversion and de novo kidney, liver, and heart studies

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Evaluation of clinical safety of conversion to Advagraf therapy in liver transplant recipients: observational study

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

First clinical experience with the new once-daily formulation of tacrolimus

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Activation of the mammalian target of rapamycin signaling pathway in hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Use of sirolimus in liver transplant recipients with renal insufficiency: a systematic review and meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Improvement of acute and chronic renal dysfunction in liver transplant patients after substitution of calcineurin inhibitors by mycophenolate mofetil

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Long-term renal function after liver transplantation is related to calcineurin inhibitors blood levels

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Sirolimus-based immunosuppressive therapy in liver transplant recipient with tacrolimus-related chronic renal insufficiency.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

End-stage renal disease (ESRD) after orthotopic liver transplantation (OLTX) using calcineurin-based immunotherapy: risk of development and treatment

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Cyclosporine nephrotoxicity

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Mycophenolate mofetil monotherapy in liver transplant recipients: a single center experience

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Effectiveness and safety of mycophenolate mofetil as monotherapy in liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Mycophenolate mofetil monotherapy in liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Conversion from Prograf to Advagraf among kidney transplant recipients results in sustained decrease in tacrolimus exposure

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Once-daily prolonged-release tacrolimus (ADVAGRAF) versus twice-daily tacrolimus (PROGRAF) in liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Safety of conversion from twice-daily tacrolimus (Prograf) to once-daily prolonged-release tacrolimus (Advagraf) in stable liver transplant recipients.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Population pharmacokinetic model and Bayesian estimator for two tacrolimus formulations--twice daily Prograf and once daily Advagraf

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Renal function improves in liver transplant recipients when switched from a calcineurin inhibitor to sirolimus

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Renal function in renal or liver transplant recipients after conversion from a calcineurin inhibitor to sirolimus

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Sirolimus in liver transplant recipients: a large single-center experience.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Sirolimus monotherapy in liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Kaposi's sarcoma after liver transplantation.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Timing of sirolimus conversion influences recovery of renal function in liver transplant recipients

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Sirolimus-associated hepatotoxicity in liver transplantation

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Sirolimus-associated hepatotoxicity in the kidney graft recipient

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

A randomized controlled trial of late conversion from calcineurin inhibitor (CNI)-based to sirolimus-based immunosuppression in liver transplant recipients with impaired renal function.

1 reference

https://api.crossref.org/works/10.1016%2FJ.TRANSPROCEED.2011.09.015

7 January 2021

Identifiers

10.1016/J.TRANSPROCEED.2011.09.015

1 reference

Europe PubMed Central

4 December 2017

1 reference

Europe PubMed Central

4 December 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q44623798&oldid=2029562124"